Beranda › Kanker Ovarium › Oklahoma › Tulsa
Uji klinis Kanker Ovarium di Tulsa, OK
4 studi untuk Kanker Ovarium mencari peserta di lokasi sekitar Tulsa (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Menerima pesertaFase 3
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Menerima pesertaFase 3
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056), Tulsa
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Menerima pesertaFase 2/3
- Oklahoma Cancer Specialists and Research Institute, Tulsa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Tulsa
Uji klinis Kanker Ovarium di kota lain
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Studi lain di Tulsa
- Gagal Jantung10 studi
- Kelebihan Berat Badan6 studi
- Obesitas5 studi
- Melanoma5 studi
- Stroke Iskemia5 studi
- PPOK4 studi
- Penyakit Parkinson4 studi
- Stenosis Katup Aorta4 studi
- Kanker Serviks4 studi
- Kanker Payudara4 studi
- Kanker Paru Non-Sel Kecil4 studi
- Depresi4 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.